Skip to main content

Table 3 Clinical characteristics of patients with SpA across Latin America

From: Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis

Country

Study

# Patients

HLA-B27 positive (%)

CRP, mg/dL

BASDAI

BASFI

ASQoL

Argentina

Marengo et al., 2008 [17]

61

n/r

n/r

27.2* (Em)

57.7* (Un)

40.3* (Em)

53.1* (Un)

5* (Em)

8* (Un)

Bellomio et al., 2008 [18]

405

46

1.9*b

4.0

3.3

5

Buschiazzo et al., 2011 [19]

402

45.3

n/r

3.8*

2.6*

n/r

Schneeberger et al., 2015 [21]

73

5

n/r

n/r

n/r

n/r

Sommerfleck et al., 2018 [22]

86

n/r

n/r

3.3 (0 c-m)

4.3 (1–2 c-m)

5.8 (≥3 c-m)

3.2 (0 c-m)

4.5 (1–2 c-m)

5.2 (≥3 c-m)

n/r

Sommerfleck et al., 2018 [23]

50

n/r

n/r

4.1*

4.2*

11.2* (PsAQoL)

Scarafia et al., 2016 (CA) [24]

92

5.6

n/r

n/r

n/r

n/r

Brazil

Sampaio-Barros et al., 2008 [26]

1036

69.5

n/r

4.1

4.5

n/r

Skare et al., 2012 [27]

1318

72.8 (W)

62.4 (AB)

35 (O)

9.3 (W)b

9.3 (AB)b

11.2 (O)b

4.0 (W)

4.3 (AB)

4.4 (O)

4.4 (W)

4.8 (AB)

4.7 (O)

7.1 (W)

8.6 (AB)

8.7 (O)

Skare et al., 2012 [28]

1424

72.8 (< 40 y)

49.5 (≥40 y)

10.3 (< 40 y)

8.02 (≥40 y)

4.15 (< 40 y)

4.47 (≥40 y)

4.6 (< 40 y)

4.7 (≥40 y)

7.8 (< 40 y)

7.8 (≥40 y)

Duarte et al., 2014 [30]

1189

67.9

n/r

4.3

4.7

7.9

Ribeiro et al., 2018 [31]

202

64.2

3.6 (W)b

3.7 (NW)b

3.6 (W)

3.7 (NW)

4.5 (W)

4.1 (NW)

7.9 (W)

6.5 (NW)

Simioni et al., 2019 [32]

85

69.2

8*

2.4*

5.1*

9.2*

Chile

Gutiérrez et al., 2008 [34]

109

66.4

16.2b

4.9

4.5

n/r

Ibáñez et al., 2019 (CA) [35]

472

n/r

n/r

6.1

5

10a

Colombia

Bautista-Molano et al., 2016 [37]

581

43.9

11.7

5.4 (Ax)

5.3 (Pr)

n/r

n/r

Santos et al., 2017 [38]

189

40.7

n/r

n/r

n/r

n/r

Costa Rica

Sáenz Castro et al., 2008 [39]

33

57.1

0.6

4.6

3.9

n/r

Mexico

Casasola-Vargas et al., 2008 [40]

172

n/r

12b

4.5

4.0

n/r

Peláez-Ballestas et al., 2013 [12]

28

14.3

n/r

n/r

n/r

n/r

Peru

Chávez-Corrales et al., 2008 [41]

60

31

n/r

n/r

n/r

n/r

Uruguay

Palleiro and Spangenberg, 2008 [42]

53

approx. 50 (AS, uSpA)

14 (PsA)

6.2 mg/L

5.3

4.3

n/r

Venezuela

Chacón et al., 2008 [43]

69

n/r

8.4b

4.4

3.6

n/r

Multinational

García-Kutzbach et al., 2011 [44]

233

57.1 (Costa Rica)

29 (El Salvador)

4 (Guatemala)c

n/r

n/r

n/r

n/r

Benegas et al., 2012 [45]

1083

71

10b

4.3

4.8

7

Bautista-Molano et al., 2018 [46]

390

n/r

n/r

n/r

3.4

n/r

  1. Continuous values are mean unless indicated (*) as median
  2. References are articles unless indicated as conference abstracts (CA)
  3. aASAS Health Index.
  4. bUnits (mg/dL or mg/L) not given in publication.
  5. cHLA-B27 test not routinely performed.
  6. AB African-Brazilian, AS ankylosing spondylitis, ASQoL Ankylosing Spondylitis Quality of Life, Ax patients with axial SpA, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, CA conference abstract, c-m comorbidities, Em employed, HLA human leukocyte antigen, I indigenous, n/r not reported, NW non-white, MR mixed race (white-black), Pr patients with peripheral SpA, PsA psoriatic arthritis, Un unemployed, uSpA undifferentiated spondyloarthritis, W white, y years